The clinical evidence submitted by the manufacturer is robust and shows superiority, in terms of longevity, of ENDURALIFE-powered CRT-D devices over other CRT-D devices implanted in the period around 2008–2010. Cost-modelling showed that longevity and price of the CRT-D device have the greatest effect on overall treatment costs. ENDURALIFE-powered CRT-D devices were shown to be cost saving compared to other CRT-D devices implanted around 2008–2010.

CRT-D device technology evolves rapidly across different manufacturers. Innovations are likely to include other components of the device and not the battery alone. It is uncertain if the evidence has direct applicability to CRT-D devices marketed today as by the time evidence is produced the devices may no longer be available.